Sarah Verhoeff

105 [89Zr]Zr-DFO-durvalumab PET/CT before durvalumab treatment in R/M SCCHN patients Figure S5. Quantitative analyses [89Zr]Zr-DFO-durvalumab per dose cohort The accumulation of [89Zr]Zr-DFO-durvalumab in the spleen, liver, bloodpool and bone marrow for each dose cohort is shown in 4A. Cohort 2mg is resembled by blue dots, cohort 10mg by yellow squares and cohort 50mg by pink triangles. The subsequent tumor-to-blood (TBT) ratio, tumor-to-liver ratio and tumor-to-spleen ratios are calculated based on the SUVmax of the largest tumor lesion and organ SUVmean values and depicted in figures 4B, 4C and 4D, respectively. 5